INTRODUCTION
============

Serotonin (5-hydroxytryptamine \[5-HT\]) has diverse functions in neuronal and non-neuronal systems. It acts as a hormone and a mitogen, as well as a neurotransmitter. At the time of its discovery (1918), 5-HT was thought to be a vasoconstrictor stored in platelets, so it was named serotonin after the Latin word *serum* and the Greek word *tonic* \[[@B1][@B2]\]. In 1937, 5-HT was found in the enterochromaffin (EC) cells of the gastrointestinal tract and named enteramine because it was thought to cause smooth muscle contraction in the gut \[[@B3]\]. It was not until 1952 that scientists reported 5-HT\'s role as a neurotransmitter \[[@B4]\]. It has since been discovered that 5-HT is a neurotransmitter associated with mood, behavior, sleep cycles, and appetite \[[@B2]\].

The synthesis of 5-HT is initiated with the hydroxylation of tryptophan by tryptophan hydroxylase (TPH), which is the rate-limiting enzyme for 5-HT synthesis. Thus, 5-HT production is regulated by the activity of TPH and the availability of tryptophan. The biological actions of 5-HT are mediated through the membrane-bound 5-HT receptors and terminated by its uptake into cells through a 5-HT transporter (SERT, Slc6a4) \[[@B5]\]. There are two isoforms of TPH. TPH1 is predominantly expressed in the peripheral tissues including the pineal gland, whereas TPH2 is exclusively expressed in the brain and the enteric nervous system \[[@B6][@B7]\]. Because 5-HT cannot cross the blood-brain barrier, the peripheral 5-HT system is functionally separate from the central 5-HT system.

Within the central and enteric nervous systems, 5-HT is synthesized and stored in the presynaptic neurons. Most 5-HT in the periphery is synthesized in EC cells \[[@B8]\] and platelets are the major storage site for circulating 5-HT. Several studies recently reported that 5-HT can be synthesized in other peripheral tissues (e.g., the heart, pancreas, and adipose tissue) and plays a role in a cell-autonomous manner \[[@B9][@B10][@B11]\].

In this review, we will discuss the recent findings on the roles of central/peripheral 5-HT in metabolism and its clinical implications for the treatment of obesity.

THE 5-HT RECEPTOR FAMILIES
==========================

5-HT regulates various physiological and pathological processes, which are mediated through numerous 5-HT receptors. The 5-HT receptors are phylogenetically ancient and present in the lowest invertebrates as well as the higher mammals \[[@B12]\]. More than fourteen 5-HT receptors in seven families are known to mediate the diverse effects of 5-HT ([Table 1](#T1){ref-type="table"}) \[[@B13][@B14]\]. All 5-HT receptors are G-protein-coupled receptors except for the 5-HT3 receptor, which is a ligand-gated cation channel \[[@B12][@B15]\].

The 5-HT1 receptor family consists of five receptors: the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptors. All these receptors are Gαi/o protein-coupled receptors that inhibit adenyl cyclase and reduce the cyclic adenosine monophosphate levels. The 5-HT2 receptor family consists of the 5-HT2A, 5-HT2B, and 5-HT2C receptors. These receptors are Gαq/11 protein-coupled receptors that mediate excitatory neurotransmission. The 5-HT2A and 5-HT2C receptors are mainly expressed in the central nervous system (CNS). The 5-HT2B receptor is expressed in peripheral tissues including the liver, kidney, heart, and stomach. It is associated with cardiac function, valvular heart disease, and heart morphogenesis. The 5-HT3 receptor is a member of the Cys-loop ligand-gated ion channel family. This channel is formed by a homopentamer of 5-HT3A subunits or heteropentamer of 5-HT3A subunits with 5-HT3B-E subunits. Opening of the channel in response to 5-HT activates an inward current and depolarizes the membrane.

REGULATION OF APPETITE BY CENTRAL 5-HT
======================================

Appetite is regulated by hypothalamic feeding circuits. Briefly, anorexigenic proopiomelanocortin (POMC) neurons release α-melanocyte-stimulating hormone, the endogenous ligand for the melanocortin 4 receptor (MC4R), to reduce appetite and food intake. Orexigenic neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons increase appetite and food intake by releasing the endogenous MC4R antagonist, AgRP, and they suppress POMC neurons by releasing γ-aminobutyric acid (GABA).

It has long been known that 5-HT in the hypothalamus plays an important role in the control of appetite and energy balance. Central 5-HT has suppressive effects on food intake and body weight. Fenfluramine, which enhances 5-HT release, is a prototypical agent that leads to serotonergic suppression of feeding \[[@B16]\]. 5-HT reuptake inhibitors and monoamine oxidase inhibitors, which can increase the central serotonergic activity, also reduce food intake \[[@B17][@B18]\]. In contrast, inhibition of central 5-HT synthesis by intraventricular injection of a TPH inhibitor induced hyperphagia and obesity in rats \[[@B19]\].

Studies using receptor-specific knock-out (KO) mice have provided more precise insight into the roles of 5-HT in appetite regulation. The involvement of central 5-HT1B and 5-HT2C receptors in the regulation of appetite was initially suggested by the anorectic effects of a central serotonergic agonist (m-chlorophenylpiperazine \[mCPP\]) \[[@B20]\]. A major contribution of 5-HT2C receptor to feeding control was confirmed by a study using *Htr2c* KO mice \[[@B21]\]. *Htr2c* KO mice are hyperphagic and obese, and the anorectic effects of mCPP do not occur in *Htr2c* KO mice \[[@B22]\]. Furthermore, studying the effects of 5-HT on the hypothalamic feeding circuit revealed that 5-HT activates POMC neurons through the 5-HT2C receptor and inhibits NPY/AgRP neurons through the 5-HT1B receptor \[[@B23]\]. Thus, central 5-HT inhibits food intake by modulating the hypothalamic feeding circuits. Many drugs targeting 5-HT2C receptor have been produced and some are currently being used in the clinical setting. However, others were discontinued because of severe complications such as pulmonary hypertension and valvular heart disease ([Table 2](#T2){ref-type="table"}) \[[@B24][@B25]\]. Recently, a selective 5-HT2C receptor agonist (Belviq, lorcaserin hydrochloride; Arena, Zofingen, Switzerland) was officially approved for use in the treatment of obesity \[[@B26]\].

Given that TPH2 is exclusively expressed in the brain, *Tph2* KO mice were expected to be hyperphagic and obese. However, *Tph2* KO mice do not show an obese phenotype although their central 5-HT level is decreased \[[@B27][@B28]\]. In addition, *Htr1b* KO mice do not become obese although they are hyperphagic \[[@B29]\]. There have also been reports supporting that central 5-HT increases the sympathetic tone and activates brown adipose tissue (BAT) \[[@B30][@B31]\]. Taken together with the known adverse effects of anti-obesity drugs with regard to their increasing the 5-HT activity in the brain, these controversial data indicate that increasing the 5-HT activity in the brain may not be a good strategy for anti-obesity treatment.

ROLES OF 5-HT IN PERIPHERAL TISSUES
===================================

Although TPH1 is widely expressed in the peripheral tissues, over 90% of the total body 5-HT is produced in the gut \[[@B32]\]. The majority of the peripheral 5-HT is stored in platelets and controls the hemodynamics upon the activation of platelets. 5-HT is also present in other peripheral tissues and acts autonomously on many cells in the cardiovascular, gastrointestinal, hematopoietic, and immune systems, as well as in the bone, liver, and placenta \[[@B33]\].

Gut
---

EC cells are dispersed throughout the intestinal mucosa and are the main source of 5-HT in the gut. The major targets of the gut-derived 5-HT (GDS) are the mucosal projections of primary afferent neurons. These include extrinsic nerves and afferent neurons. The extrinsic nerves transmit sensations of nausea and discomfort to the CNS. There are two types of intrinsic primary afferent neurons (IPANs). The submucosal IPAN regulate the peristaltic and secretory reflexes, whereas myenteric IPAN regulate giant migrating contractions. The 5-HT secreted from myenteric neurons mediates fast and slow excitatory neurotransmission and regulates gastrointestinal motility.

Many 5-HT receptor agonists/antagonists are already used to regulate gut motility in the clinical setting ([Table 3](#T3){ref-type="table"}). Pressure, acid, and/or cancer therapeutic agents are known to release 5-HT from EC cells, which provokes abdominal discomfort and nausea \[[@B34][@B35]\]. 5-HT3 receptor antagonists, such as ondansetron (Zofran; GSK, London, UK), granisetron (Kytril; Roche Laboratories, Basel, Switzerland), or alosetron (Lotronex; GSK, London, UK), alleviate the 5-HT-induced discomfort that extrinsic sensory nerves convey to the CNS. Irritable bowel syndrome (IBS) is a disease linked to the serotonergic system. The persistent visceral hypersensitivity of the bowel in IBS patients can be blunted by the administration of a 5-HT4 receptor agonist (Tegaserod; Novartis, Basel, Switzerland) \[[@B36]\]. Thus, drugs that inhibit the 5-HT3 receptor or enhance the 5-HT4 receptor have been used to treat IBS.

Many studies suggest that 5-HT plays a role in the pathogenesis of gastrointestinal diseases by affecting the production of pro-inflammatory mediators and the immune system \[[@B37]\]. 5-HT receptors have been identified on various immune cells such as lymphocytes, monocytes, macrophages, and dendritic cells \[[@B38][@B39]\]. The T lymphocyte-derived 5-HT may act as an autocrine factor and has demonstrated a fundamental role as an intrinsic cofactor in T-cell activation and function through the 5-HT7 receptor \[[@B40]\].

Liver
-----

5-HT is known to regulate liver regeneration. Partial hepatectomy has been widely used as an experimental model to understand the role of 5-HT in liver regeneration. The number of platelets (filled with 5-HT) strongly correlates with the hepatocyte proliferative capacity \[[@B41]\]. In contrast, several studies using SERT-deficient rats reported that the regenerative process is not influenced when the platelet 5-HT level is reduced \[[@B42]\]. Thus, the mechanism underlying liver regeneration is more complex than has previously been thought, and more studies are needed to elucidate the main source of 5-HT to regulate liver regeneration. To directly examine the function of 5-HT in liver regeneration, partial hepatectomy was performed on *Tph1* KO and wild type (WT) control mice. All markers of hepatocyte proliferation were reduced in *Tph1* KO mice, suggesting that 5-HT is involved in the induction of hepatocyte proliferation after a major loss of hepatic tissue \[[@B43]\]. It has also been demonstrated that 5-HT can promote liver regeneration after liver injury through the 5-HT2 receptor or 5-HT7 receptor \[[@B44][@B45]\].

Crane et al. \[[@B46]\] reported a role of peripheral 5-HT in the liver after exposure to a high fat diet (HFD). When fed a HFD, WT mice become obese and develop fatty liver disease. In contrast, *Tph1* KO mice do not develop a fatty liver after exposure to a HFD and have reduced fat accumulation in the liver. 5-HT increases hepatic glucose uptake and fat content in liver \[[@B47][@B48]\]. The duodenal 5-HT content increases in *ob/ob* mice and treatment with a 5-HT3 receptor antagonist caused the reduction of the elevated 5-HT levels and an increase in SERT in the duodenum. In these mice, the 5-HT3 receptor antagonist also reduced the fat content, inflammation, and necrosis of the liver \[[@B48]\].

With regard to insulin resistance, Sumara et al. \[[@B8]\] reported that inhibition of GDS improves the glucose tolerance in mice fed a HFD. In hepatocytes, GDS signaling through the 5-HT2B receptor promotes gluconeogenesis. In addition, GDS prevents glucose uptake into hepatocytes in a glucose transporter 2-dependent manner. Therefore, gut-specific *Tph1* KO mice and liver-specific *Htr2b* KO mice showed improved glucose tolerance compared to WT mice \[[@B8]\].

Pancreatic β-cells and the impact of 5-HT on diabetes mellitus
--------------------------------------------------------------

It has long been known that 5-HT is present in the same vesicle with insulin in pancreatic β-cell after preloading of 5-hydroxytryptophan, a precursor of 5-HT, and 5-HT has been associated with the regulation of the blood glucose concentration \[[@B49][@B50]\]. Recently, 5-HT has been identified as a downstream molecule of placental lactogen that mediates the adaptation of β-cells to pregnancy \[[@B10]\]. In response to the lactogens produced during pregnancy, the expression of Tph1 rises sharply in pancreatic β-cells, resulting in massive production of 5-HT in β-cells \[[@B10]\]. Islet 5-HT acts in an autocrine/paracrine manner through the 5-HT3 receptor to increase the glucose responsiveness of β-cells and thereby increases the overall islet glucose-stimulated insulin secretion (GSIS) \[[@B51][@B52]\]. In addition, the expression of the 5-HT2B receptor increases during mid-gestation to stimulate β-cell proliferation and increase the β-cell mass, whereas 5-HT1D receptor expression increases at the end of gestation to reduce the β-cell mass \[[@B10]\].

5-HT also regulates insulin secretion in a diet-induced insulin-resistant state. The β-cell-specific *Tph1* KO mice and *Htr3a* KO mice developed glucose intolerance compared to WT mice after exposure to an HFD. The GSIS was impaired in islets isolated from HFD-fed *Htr3a* KO and β-cell-specific *Tph1* KO mice, and 5-HT treatment improved the insulin secretion from the islets of β-cell-specific *Tph1* KO mice, but not from the *Htr3a* KO islets \[[@B51]\]. In addition, 5-HT production has been observed in the embryonic pancreas. In particular, TPH1 expression is upregulated in newborn β-cells during the perinatal period while β-cells are actively proliferating \[[@B53]\]. Given that β-cells produce 5-HT under two physiological conditions of β-cell proliferation, the perinatal period and pregnancy, 5-HT is thought to be an important regulator of β-cell proliferation as well as insulin secretion \[[@B10][@B51][@B52][@B54]\].

Adipose tissues
---------------

The biological functions of peripheral 5-HT in the regulation of energy homeostasis have been extensively studied using chemical agonists and antagonists since the 1960s. By taking advantage of mouse genetic studies, it has become possible to better understand the precise roles of 5-HT in energy metabolism. SERT KO mice exhibit an obese phenotype although they are expected to be slim due to the anorexigenic effects of central 5-HT \[[@B55]\]. Body weight is reduced in *Tph1* and *Tph2* double KO mice, as well as *Tph1* KO mice \[[@B27][@B28]\]. However, the body weights of gut-specific *Tph1* KO mice are comparable to those of WT control mice \[[@B8]\]. These data suggest that 5-HT, other than GDS, may play a role in regulating systemic energy homeostasis. Recently, two independent studies have highlighted the role of adipocyte-derived 5-HT in energy storage in the white adipose tissue (WAT) and energy expenditure in the BAT \[[@B11][@B46]\]. In a diet-induced mouse model of obesity, the Tph1 expression and tissue 5-HT concentrations were elevated in adipose tissues \[[@B11][@B46]\]. *Tph1* KO mice were protected from obesity and the related metabolic dysfunctions \[[@B46]\]. *Tph1* KO mice gained significantly less weight and had lower adiposity when fed an HFD. The glycemic control is also improved in *Tph1* KO mice, although the glucose uptake was similar in the muscle, liver and heart, indicating that the BAT make a major contribution to the increase in the basal metabolic rate \[[@B46]\]. Indeed, energy expenditure was enhanced in *Tph1* KO mice when they were fed an HFD. The BAT activity increased in a Ucp1-dependent manner in *Tph1* KO mice. The obesogenic actions of peripheral 5-HT were also confirmed using a peripheral TPH inhibitor (LP-533401) \[[@B11][@B46]\]. Furthermore, a cell autonomous effect of 5-HT in adipose tissue has been shown in adipocyte-specific *Tph1* KO mice \[[@B11]\]. The adipocyte-specific *Tph1* KO induced Ucp1 and Dio2 expression in the BAT and subcutaneous WAT \[[@B11]\].

Regarding brown fat thermogenesis, the 5-HT3 receptor plays a major role in diet-induced thermogenesis \[[@B11]\]. Diet-induced thermogenesis was robustly increased in the BAT of *Htr3a* KO mice fed a HFD \[[@B11]\]. In addition to the role of 5-HT in the BAT, *in vitro* experiments using 3T3-L1 adipocytes provided a hint about the role of 5-HT in adipogenesis \[[@B11][@B56]\]. It was known that 5-HT can increase the lipid accumulation in human and mouse fat cells \[[@B57]\]. It was also known that 5-HT2A receptor expression is increased in the hypertrophied 3T3L1 adipocytes and WAT of *db/db* mice, and the activation of the 5-HT2A receptor reduces adiponectin expression in hypertrophied 3T3L1 adipocytes \[[@B58]\]. Treatment with a 5-HT2A receptor antagonist increased the lipid accumulation and circulating adiponectin levels \[[@B11][@B59]\]. An antagonist for the 5-HT2A receptor inhibited adipogenesis \[[@B56]\]. Thus, 5-HT increases energy storage in the WAT through 5-HT2A receptor and inhibits energy expenditure in the BAT through 5-HT3 receptor. Taken together, these recent findings suggest that 5-HT negatively regulates the sensitivity of BAT to β-adrenergic stimulation.

GENETICS OF 5-HT AND OBESITY
============================

To understand the genetic basis of obesity, many genome-wide association studies (GWAS) have been conducted. Several GWAS revealed genetic associations between the serotonergic system and obesity. The first association between TPH1 and obesity was identified through a GWAS in Koreans \[[@B60]\]. A genetic variant of TPH1 (rs623580) was associated with the body mass index in a GWAS comprising 8,842 subjects (*P*=0.0047), and single nucleotide polymorphisms (SNPs) of TPH1 were significantly associated with weight gain during pregnancy in women with gestational diabetes mellitus. Several GWAS revealed associations between SNPs of the 5-HT receptors and obesity ([Table 4](#T4){ref-type="table"}) \[[@B60][@B61][@B62][@B63][@B64][@B65][@B66][@B67]\]. SNPs of HTR2A had strong associations with obesity in both European and Asian ethnic groups \[[@B61][@B62][@B63][@B67]\]. SNPs in the promoter (rs6311, -1438 \[G/A\]) and intron (rs2070040, 2416 \[C/T\]) were associated with metabolic syndrome in a study of 934 European subjects. Central obesity (a high waist circumference) showed a significant association with the -1438 GG genotype (odds ratio \[OR\], 1.57; *P*=0.003), and the -1438 GG and 2416 TT genotypes were associated with an increased risk of metabolic syndrome (OR, 1.71; *P*=0.016) \[[@B62]\]. In 478 healthy Chinese subjects, 12 SNPs in seven genes (MAOB, SLC18A1, HTR2A, HTR2C, HTR3B, HTR4, and HTR7) were significantly associated with the body mass index \[[@B67]\]. These genetic studies indicate that the identification of serotonergic system defects can be used for risk prediction and to develop individualized treatments for obesity and metabolic syndrome.

CONCLUSIONS
===========

The human body has two separate serotonergic systems: the central 5-HT and peripheral 5-HT systems ([Fig. 1](#F1){ref-type="fig"}). With regard to the central 5-HT system, increasing the 5-HT signaling has been utilized therapeutically to reduce body weight by reducing appetite. In 2010, the U.S. Food and Drug Administration approved a new selective 5-HT2C receptor agonist (Belviq, lorcaserin hydrochloride) for use in the treatment of obesity \[[@B26]\]. This drug was also approved by the Ministry of Food and Drug Substances in Korea. In peripheral tissues, suppressing 5-HT signaling might represent a new target for anti-obesity treatment by increasing energy expenditure and improving insulin resistance \[[@B11][@B46]\]. Systemic TPH1 inhibitors and a peripheral TPH1 inhibitor (LP-533401) have already been patented for treating diabetes and obesity \[[@B68][@B69]\]. However, there have not yet been any clinical trials using these drugs to treat obesity. Recent GWAS results support the clinical importance of serotonergic regulation in human metabolism, but most of these studies have small sample sizes and have not been validated. Therefore, to enhance our understanding of the role of 5-HT in metabolism and to provide effective therapeutic applications of 5-HT, more clinical studies are needed on drugs that can regulate the serotonergic system, and genetic studies are needed to investigate the associations between 5-HT and metabolic diseases.
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![Roles of 5-hydroxytryptamine (5-HT) on metabolic organs. Central 5-HT regulates appetite and controls metabolic organs through sympathetic/parasympathetic nervous system. Peripheral 5-HT regulates glucose metabolism, insulin resistance and energy expenditure in an autocrine/paracrine or endocrine manner. TPH, tryptophan hydroxylase; HTR, 5-HT receptor; β-AR β-adrenergic receptor; BAT, brown adipose tissue; WAT, white adipose tissue.](dmj-40-89-g001){#F1}

###### The 5-HT receptors, their functions and the specific receptor agonists/antagonists

![](dmj-40-89-i001)

  Receptor subtype                  Structure   Transduction system
  --------------------------------- ----------- ---------------------------------------
  5-HT1A                            GPCR        ↓cAMP
  G-protein coupled- K^+^ current               
  5-HT1B                            GPCR        ↓cAMP
  5-HT1D                            GPCR        ↓cAMP
  5-HT1E                            GPCR        ↓cAMP
  5-HT1F                            GPCR        ↓cAMP
  5-HT2A                            GPCR        ↑PCR
  5-HT2B                            GPCR        ↑PCR
  5-HT2C                            GPCR        ↑PCR
  5-HT3                             LGIC        Ion conductance (K^+^, Na^+^, Ca^2+^)
  5-HT4                             GPCR        ↑cAMP
  5-HT5A                            GPCR        ↓cAMP
  Ca^2+^ mobilization                           
  K^+^ current                                  
  5-HT5B                            GPCR        Not known
  5-HT6                             GPCR        ↑cAMP
  5-HT7                             GPCR        ↑cAMP

5-HT, 5-hydroxytryptamine; GPCR, G protein coupled receptor; cAMP, cyclic adenosine monophosphate; PCR, phosphocreatine; LGIC, ligand-gated ion channel.

###### Anti-obesity drugs that work by regulating the central serotonergic system

![](dmj-40-89-i002)

  Name or code                                          Company               Action                              Current status
  ----------------------------------------------------- --------------------- ----------------------------------- ---------------------
  Lorcaserin                                            Arena Pharma          5-HT2C receptor agonist             FDA approved.
  ATHX-105                                              Athersys              5-HT2C receptor agonist             Withdrawn
  BVT.74316                                             Biovitrum             5-HT6 receptor antagonist           Withdrawn
  PRX-07034                                             EPIX Pharma           5-HT6 receptor antagonist           Phase lI
  Tesofensine                                           NeuroSearch           5-HT/DA/NA reuptake inhibitor       Phase III
  Dov-21,947                                            Dov Pharmaceuticals   5-HT/DA/NA reuptake blocker         Phase ll
  Sibutramine                                                                 5-HT/NA reuptake inhibitor          FDA approved (1997)
  Withdrawn due to cardiovascular complication (2010)                                                             
  Fenfluramine/phentermine                                                    5-HT releasing agent/NA stimulant   FDA approved (1973)
  Withdrawn due to cardiovascular complication (1997)                                                             

Adapted from ClinicalTrials.gov \[[@B25]\].

5-HT, 5-hydroxytryptamine; FDA, Food and Drug Administration; DA, dopamine; NA, noradrenaline.

###### Effects of 5-HT receptor agonists/antagonists in the gut
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  Class                                   Compound                                    Effect
  --------------------------------------- ------------------------------------------- --------------------------------
  5-HT3 receptor antagonist               Ondansetron                                 Slower small bowel transit
  Granisetron                             Decreased intestinal secretion              
  Alosetron                               Inhibition of colonic response to feeding   
  Cilansetron                             Slower colonic transit                      
  5-HT3 receptor agonist                  MKC-733                                     Slower emptying of liquids
  Faster small bowel transit                                                          
  Stimulation of interdigestive phase 3                                               
  5-HT4 receptor agonist                  Tegaserod                                   Faster gastric emptying
  Prucalopride                            Enhanced gastric accommodation              
  Renzapride                              Faster small bowel and colonic transit      
  Cisapride                               Enhanced intestinal secretion               
  5-HT1 receptor agonist                  Sumatriptan                                 Enhanced gastric accommodation
  Buspirone                               Slower gastric emptying                     
  R-137696                                Stimulation of interdigestive phase 3       

5-HT, 5-hydroxytryptamine.

###### The results of genome-wide association studies on the serotonergic system and obesity

![](dmj-40-89-i004)

  Study                                  Ethnicity   Sample size, n   SNP ID      Gene      Chromosome   Allele   Association
  -------------------------------------- ----------- ---------------- ----------- --------- ------------ -------- -------------------------------------
  Kwak et al. (2012) \[[@B60]\]          Korean      8,842            rs623580    TPH1      11           A/T      BMI and WC
  Rosmond et al.(2002) \[[@B61]\]        Swedish     284              rs6311      HTR2A     13           C/T      BMI, WHR
  Halder et al. (2007) \[[@B62]\]        European    934              rs6311      HTR2A     13           C/T      Central obesity, metabolic syndrome
  rs2070040                              HTR2A       13               A/G                                         
  Li et al. (2014) \[[@B63]\]            European    1,982            rs912127    HTR2A     13           A/G      BMI
  American                               rs1745837   HTR2A            13          C/T                             
  Opgen-Rhein et al. (2010) \[[@B64]\]   German      128              rs498207    HTR2C     X            C/T      Weight gain
  Suviolahti et al. (2003) \[[@B65]\]    Finnish,    2,104            rs2011162   SLC6A14   X            C/G      BMI
  Swedish                                rs2071877   SLC6A14          X           C/T                             
  Corpeleijn et al. (2010) \[[@B66]\]    European    722              rs2011162   SLC6A14   X            C/G      BMI, fat oxidation in women
  Chen et al. (2013) \[[@B67]\]          Chinese     478              rs1018079   SLC18A1   8            A/G      BMI
  rs11214769                             HTR3B       11               A/G                                         
  rs2224721                              HTR2A       13               A/C                                         
  rs4911871                              HTR2C       X                A/G                                         

SNP, single nucleotide polymorphism; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio.
